Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study
National Cancer Center Hospital East · Yonsei University · +23 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
329
total citations
- FWCI
- 98.45
- Percentile
- 100%
- References
- 24
Citations per year
Authors
24- KSKohei ShitaraCorresponding
National Cancer Center Hospital East
- SYSun Young Rha
Yonsei University, Yonsei University Health System
- LWLucjan Wyrwicz
The Maria Sklodowska-Curie National Research Institute of Oncology
- TOTakashi Oshima
Kanagawa Prefectural Hospital Organization, Kanagawa Cancer Center
- NKNina Karaseva
Topics & keywords
Topics
Keywords
- Medicine
- Pembrolizumab
- Internal medicine
- Placebo
- Docetaxel
- Oncology
- Interim analysis
- Cancer
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.